Skip to main content
CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD. logo

CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 688443 ISIN · CNE100006KG8 LEI · 300300SXEUTIHERZQX68 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 331 across all filing types
Latest filing 2026-05-25 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688443

About CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD.

https://www.genrixbio.com/

Chongqing Genrix Biopharmaceutical Co., Ltd. specializes in the research, development, and large-scale manufacturing of therapeutic monoclonal antibodies and recombinant proteins. The company focuses on addressing unmet medical needs in oncology, autoimmune diseases, and metabolic disorders through a pipeline of biosimilars and innovative biologics. Its technical infrastructure includes integrated platforms for cell line development, process optimization, and high-volume mammalian cell culture production. Genrix maintains advanced facilities compliant with international quality management standards to support the commercialization of high-quality biopharmaceutical products. The organization leverages its R&D capabilities to streamline the transition from drug discovery to clinical application and market supply.

Recent filings

Filing Released Lang Actions
2025年年度股东会会议资料
AGM Information Classification · 90% confidence The document is clearly the annual shareholders meeting materials (“2025年年度股东会会议资料”) including meeting notice, agenda, and resolutions for the company’s 2025 AGM. It provides the materials to be shared at the Annual General Meeting, matching the AGM Information category.
2026-05-25 Chinese
国泰海通证券股份有限公司关于重庆智翔金泰制药股份有限公司2025年度持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2025年度持续督导工作现场检查报告" which translates to "2025 Annual Continuous Supervision On-site Inspection Report" by the sponsor (underwriter) for a company listed on the Shanghai Stock Exchange's STAR Market. It details the sponsor's on-site inspection of the company's governance, internal controls, information disclosure, independence, related party transactions, use of raised funds, and operational status during the 2025 continuous supervision period. The document includes detailed findings, opinions, and conclusions from the sponsor's inspection. It is a formal report on the sponsor's regulatory supervision activities rather than a general annual report or audit report. It is not a brief announcement or a certification letter but a substantive report on the sponsor's continuous supervision work. This type of document fits best under the category of Audit Report / Information (AR), as it is a standalone report related to regulatory compliance and internal control inspection by the sponsor, distinct from the full annual report (10-K) or interim report (IR). The document length (2877 characters) is consistent with a detailed report but not a full annual report. Therefore, the classification is AR with high confidence.
2026-04-29 Chinese
董事、高级管理人员薪酬管理制度
Remuneration Information Classification · 95% confidence The document is titled '董事、高级管理人员薪酬管理制度' which translates to 'Remuneration Management System for Directors and Senior Management' of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. It details the principles, structure, management, performance evaluation, and responsibility related to the remuneration of directors and senior management. It references relevant laws and governance codes, and outlines the remuneration policy and procedures. There are no financial statements or earnings data, nor is it an announcement or a report publication notice. The content fits the definition of a Remuneration Information report, which details compensation for top executives and directors.
2026-04-29 Chinese
国泰海通证券股份有限公司关于重庆智翔金泰生物制药股份有限公司2026年度日常关联交易预计的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (Guotai Haitong Securities Co., Ltd.) regarding the expected daily related-party transactions for the year 2026 of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. It includes detailed transaction categories, amounts, related parties, approval procedures, and compliance with regulatory rules. The document is not a financial report like an annual or interim report, nor is it an earnings release or a call transcript. It is a specialized audit or verification opinion related to regulatory compliance and internal controls over related-party transactions. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles or regulatory compliance verifications excluding full annual reports. The document length (5635 characters) and content confirm it is a substantive report, not merely an announcement or certification letter. Therefore, the correct classification is AR with high confidence.
2026-04-29 Chinese
关于2026年度申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the board of directors of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. regarding the application for a comprehensive credit limit for the year 2026. It details the intention to apply for increased credit facilities from banks and financial institutions, including the types of credit products involved and the authorization for the chairman to handle related procedures. There is no financial statement, earnings data, or detailed financial analysis present. The document is clearly an update on financing activities, specifically about credit limits and borrowing capacity. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or a regulatory filing. Confidence is high due to clear content focus on financing.
2026-04-29 Chinese
关于独立董事独立性情况的专项意见
Board/Management Information Classification · 95% confidence The document is a special opinion on the independence of independent directors of the company, referencing compliance with regulatory rules and internal governance documents. It is a formal statement from the board regarding the independence status of specific directors. It does not contain financial data, audit results, or detailed governance rules but is a regulatory compliance statement related to board management. This fits best under Board/Management Information (MANG), which covers announcements about board or senior management matters, including independence assessments of directors.
2026-04-29 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.